IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: FENG et al.

Serial No.: 10/718,948 Art Unit: 1617

Filed: November 20, 2003 Examiner: Carlic K. HUYNH

For: METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE b-ADRENERGIC PATHWAYS

I hereby certify that this correspondence is being transmitted via The Office electronic filing system in accordance with 37 CFR 1.6(a) (4)

The Office of Transmission)

Anna M. Pignaloni
(Name of applicant, assignee, Registered Representative or Depositor)

Commissioner for Patents

Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §1.97(e)

July 13,2007
(Date of Signature)

In accordance with 37 C.F.R. §1.97(e), certification is hereby made that:

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

☐ No item of information contained in the Information
Disclosure Statement was cited in a communication from a foreign
patent office, in a counterpart foreign application, and, to the
knowledge of the undersigned after making reasonable inquiry, no item
of information contained in this Information Disclosure Statement,

was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

Samuel M. Kais Reg. No. 42,705

Attorney for Applicants

Scios Inc.

c/o Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933

Phone: (650) 564-4146 Fax: (650) 564-2101